Cellectar Biosciences, Inc.
CLRB
$0.2515
$0.00732.99%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -2.36M | -14.66M | -919.40K | -26.64M | -7.88M |
| Total Depreciation and Amortization | 68.60K | 68.60K | 66.00K | 88.50K | 70.00K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -8.56M | 3.21M | -11.64M | 15.43M | -3.37M |
| Change in Net Operating Assets | -63.60K | 2.22M | -1.65M | -2.24M | 1.58M |
| Cash from Operations | -10.91M | -9.17M | -14.14M | -13.36M | -9.60M |
| Capital Expenditure | -61.30K | 0.00 | -21.30K | -21.60K | -266.80K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -61.30K | 0.00 | -21.30K | -21.60K | -266.80K |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 0.00 | 17.56M | 0.00 | 43.85M | 441.00K |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 0.00 | 17.56M | 0.00 | 43.85M | 441.00K |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -10.97M | 8.39M | -14.16M | 30.47M | -9.42M |